12/17
08:15 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/16
08:00 am
dare
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Medium
Report
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
12/10
08:00 am
dare
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Medium
Report
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
12/4
08:00 am
dare
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Medium
Report
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
11/15
08:03 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/14
04:01 pm
dare
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Medium
Report
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
11/13
08:00 am
dare
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
High
Report
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
11/7
01:42 pm
dare
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
11/7
08:00 am
dare
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
Medium
Report
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
10/24
08:08 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/23
12:30 pm
dare
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Medium
Report
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
10/21
08:05 am
dare
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Medium
Report
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
9/26
12:57 pm
dare
Bill Gates helped fund birth control microchip but didn't invent it | Fact check [USA TODAY]
Low
Report
Bill Gates helped fund birth control microchip but didn't invent it | Fact check [USA TODAY]